- Home
- ENTA vs NRO Comparison
ENTA vs NRO Comparison
Compare ENTA & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- NRO
- Stock Information
- Founded
- ENTA 1995
- NRO 2003
- Country
- ENTA United States
- NRO United States
- Employees
- ENTA N/A
- NRO N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- ENTA Health Care
- NRO Finance
- Exchange
- ENTA Nasdaq
- NRO Nasdaq
- Market Cap
- ENTA 164.6M
- NRO 156.7M
- IPO Year
- ENTA 2013
- NRO N/A
- Fundamental
- Price
- ENTA $7.84
- NRO $3.27
- Analyst Decision
- ENTA Strong Buy
- NRO
- Analyst Count
- ENTA 5
- NRO 0
- Target Price
- ENTA $20.20
- NRO N/A
- AVG Volume (30 Days)
- ENTA 164.6K
- NRO 239.4K
- Earning Date
- ENTA 08-11-2025
- NRO 01-01-0001
- Dividend Yield
- ENTA N/A
- NRO 11.41%
- EPS Growth
- ENTA N/A
- NRO N/A
- EPS
- ENTA N/A
- NRO N/A
- Revenue
- ENTA $64,806,000.00
- NRO N/A
- Revenue This Year
- ENTA N/A
- NRO N/A
- Revenue Next Year
- ENTA $1.65
- NRO N/A
- P/E Ratio
- ENTA N/A
- NRO N/A
- Revenue Growth
- ENTA N/A
- NRO N/A
- 52 Week Low
- ENTA $4.09
- NRO $2.51
- 52 Week High
- ENTA $13.37
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- ENTA 45.61
- NRO 51.62
- Support Level
- ENTA $7.28
- NRO $3.23
- Resistance Level
- ENTA $8.86
- NRO $3.37
- Average True Range (ATR)
- ENTA 0.53
- NRO 0.05
- MACD
- ENTA -0.18
- NRO -0.00
- Stochastic Oscillator
- ENTA 29.63
- NRO 40.59
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").